Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Platelet turnover in advanced diabetes

P D Winocour1

  • 1Department of Pathology, McMaster University, Hamilton, Ontario, Canada.

European Journal of Clinical Investigation
|February 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel bicyclic lactam inhibitors of thrombin: potency and selectivity optimization through P1 residues.

Bioorganic & medicinal chemistry letters·2001
Same author

Potent and selective bicyclic lactam inhibitors of thrombin. Part 4: transition state inhibitors.

Bioorganic & medicinal chemistry letters·2001
Same author

In vitro and in vivo properties of bicyclic lactam inhibitors: a novel class of low molecular weight peptidomimetic thrombin inhibitors.

Thrombosis research·2000
Same author

Incorporation of an Asp-Ser sequence to form an RGDS-like motif in hirutonin: the effect on in vitro platelet function.

Thrombosis research·2000
Same author

The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 1.

Bioorganic & medicinal chemistry letters·1999
Same author

The design of potent and selective inhibitors of thrombin utilizing a piperazinedione template: part 2.

Bioorganic & medicinal chemistry letters·1999

Platelets contribute to atherosclerosis in non-diabetics. In diabetes, platelet hypersensitivity and interaction with injured vessels are unclear, potentially increasing vascular risks.

Area of Science:

  • Cardiovascular Research
  • Diabetes Complications
  • Hemostasis and Thrombosis

Background:

  • Platelets are implicated in atherosclerosis and thromboembolic events in non-diabetic individuals.
  • Diabetes mellitus is a known risk factor for vascular complications, but the precise mechanisms involving platelets remain unclear.
  • While platelets from diabetic subjects show in vitro hypersensitivity to agonists, their in vivo behavior and contribution to vascular disease are not well understood.

Purpose of the Study:

  • To investigate the in vivo behavior of platelets in the context of diabetes and vascular injury.
  • To determine if platelet hypersensitivity observed in vitro persists in vivo in diabetic conditions.
  • To elucidate the contribution of altered platelet function to the increased vascular complication risk in diabetes.

Related Experiment Videos

Main Methods:

  • Review of existing literature on platelet function in diabetes and vascular injury.
  • Analysis of studies using animal models (rats, rabbits) to assess platelet interaction with experimentally injured vessels.
  • Examination of platelet survival and turnover as indicators of in vivo platelet behavior.

Main Results:

  • Studies in rats and rabbits suggest diabetes increases platelet interaction with injured vessels and thrombus formation.
  • Platelet survival and turnover measurements may not accurately reflect in vitro sensitivity or behavior at injured sites.
  • The role of platelet changes versus vessel wall changes in diabetes-related vascular events is not definitively established.

Conclusions:

  • The in vivo role of platelet hypersensitivity and altered interaction with injured vessels in diabetes-related vascular complications requires further investigation.
  • Clarifying whether changes reside in platelets or the vessel wall is crucial for understanding diabetes-associated vascular disease.
  • Further research is needed to link observed platelet behaviors in diabetic models to clinical vascular risks.